MP Advisors Market Research Reports

Title published price

Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era • Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs • Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain

By MP Advisors

Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chr ...

01-Sep-2016 $3500

India Pharma Outlook 2016: Milestones to Watch – Growth from Exports and Domestic Getting Better, Implementation of Policies under “Make-in-India”, Overture of A New Ministry

By MP Advisors

2016 will be a crucial for drug makers and consumers. During ‘Make-in-India' week in Mumbai, Govt. highlighted many amendments or introduction of new policies with an aim to make India as a major hub for end to end drug discovery. To boost drug di ...

17-Mar-2016 $1500

Large Cap Pharma US & EU Outlook 2016: Maximizing Their Strength On Fewer Therapy Class, Personalized Medicine, Novel Target And Biosimilars For Future Growth

By MP Advisors

Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, v ...

17-Mar-2016 $2000

Japan Pharma Outlook 2016 : JP Giants leaning in for becoming a Speciality Global Pharma

By MP Advisors

Sakigake designation - A Push from government to "Innovate"! "Essential drugs" exemption from Z2 rule- Balancing long listed pricing pressure! Authorized Generics, Biosimilars, and Patent Litigations - Avenues to grow in JP Generic ...

10-Mar-2016 $2500

Japan Biosimilar- Active Players In Quest of a Specialty & Niche BS space

By MP Advisors

Filgrastim BS and Lantus BS Approval- Encouraging uptake and a lesson to fast track JP approval based on Ex-Japan data! Remicade biosimilar “NK” – A slow start does not pull back NK in starting PhIII for Herceptin BS in J ...

01-Jan-2016 $4000

Rising Stars Outlook 2016 :New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)

By MP Advisors

Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there ...

01-Jan-2016 $2000

Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies

By MP Advisors

Sales of Hepatitis C drugs crossed ~$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative.  Improved diagnosis rate and change in tr ...

01-Dec-2015 $3500

BUCCAL DRUG DELIVERY SYSTEMS: OPPORTUNITIES AND CHALLENGES IN BUCCAL, SUBLINGUAL FILMS, TABLETS & SPRAYS - Detailed analysis on Technologies and Pipeline Development

By MP Advisors

Within the oral mucosal cavity, the buccal region offers an attractive route of administration for systemic drug delivery. The mucosa has a rich blood supply and it is relatively permeable.  The buccal mucosa offers several advantages for con ...

01-Oct-2015 $3000

India Pharma Outlook 2015: Accelerating growth to the next level: Moving up the value chain beyond Generics

By MP Advisors

Domestic sales improved in 2014, recovering from the slump in the 2013 caused by the market's reaction to the new drug pricing policy. In 2015, growth is expected to continue to be healthy, as the momentum continues and improving economic growth a ...

02-Feb-2015 $2000

Japan Pharma Outlook 2015: 2015 -Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives

By MP Advisors

The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic or innovator. The most of the companies are revalidating their domestic (and thus overseas) strate ...

27-Jan-2015 $2000

Sri Lanka Pharma Market Outlook 2015: More beyond Importers & Distributors

By MP Advisors

With the recent development, Sri Lanka's aim of developing a pharma industry should be to penetrate the global market since the internal market is not sufficient for any big firm to operate at optimum levels. According to a report published by Ind ...

26-Jan-2015 $2000

Global Pharma US & EU Outlook 2015 : First -In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies

By MP Advisors

Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisition. In the recent years several new therapies have been approved in the ...

26-Jan-2015 $2000

Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

By MP Advisors

All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche in ...

26-Jan-2015 $2000

Dietary Supplements: World of Opportunities In the Indian Healthcare Market

By MP Advisors

Increasing rate of chronic diseases has emphasized the need of Prevention over Intervention.  These proactive health solutions include nutritional supplements which promise medical or health benefits and fall between the food and pharma chain – ‘Nutr ...

21-Jan-2015 $2000

Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease

By MP Advisors

While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important ...

21-Jan-2015 $3000

Regenerative Medicine and Stem cell based Cell therapies - Drugs of the Future Offering Hope for Cure

By MP Advisors

Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology is discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing the ...

21-Jan-2015 $3000

New Phase of Mab biosimilar knocks the door Biosimilar Oppurtunities In Japan

By MP Advisors

The launch of Remicade biosimilar in Dec-2014 in the Japan pharma market demonstrated its changing regulatory environment; it is faster than U.S. in adapting to biosimilar use. After nine years of continuous efforts by the JP government to promote in ...

21-Jan-2015 $4000

India Rising Stars Outlook 2015: Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there

By MP Advisors

Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there. However, there have a been a new generation of entrepreneurs who have who ventured into the drug discovery path backed ...

21-Jan-2015 $1000

Global Rising Stars Outlook 2015: Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets.

By MP Advisors

Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets , approaches and biology is discovered. One field which is poised to bring a paradigm change in the way diseases are treated in the next decades is t ...

21-Jan-2015 $2000

Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain

By MP Advisors

Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined. Current analgesics for persistent pain are relatively ineffective, are associated with significant adverse effects or abuse liability, ...

13-Jan-2015 $3000